Selling, General, and Administrative Costs: Novartis AG vs Walgreens Boots Alliance, Inc.

A Comparative Analysis of SG&A Expenses: Novartis AG vs Walgreens Boots Alliance, Inc.

In the ever-evolving landscape of global business, understanding the financial dynamics of industry giants is crucial. Selling, General, and Administrative (SG&A) expenses are a key indicator of a company's operational efficiency. From 2014 to 2023, Walgreens Boots Alliance, Inc. consistently outpaced Novartis AG in SG&A expenses, with Walgreens' costs peaking at approximately $25.5 billion in 2023, a 44% increase from 2014. In contrast, Novartis AG's expenses showed a more stable trend, peaking at around $16.5 billion in 2018 before declining to $12.5 billion in 2023. This disparity highlights Walgreens' expansive operational scale compared to Novartis. Notably, data for Novartis in 2024 is missing, suggesting potential shifts in reporting or strategy. As these companies navigate the complexities of the global market, their SG&A trends offer valuable insights into their strategic priorities and financial health.